2022
DOI: 10.1038/s41375-022-01625-x
|View full text |Cite
|
Sign up to set email alerts
|

The WHO Classification of Haematolymphoid Tumours

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1

Citation Types

0
40
0
3

Year Published

2022
2022
2024
2024

Publication Types

Select...
5
4

Relationship

1
8

Authors

Journals

citations
Cited by 83 publications
(43 citation statements)
references
References 14 publications
0
40
0
3
Order By: Relevance
“…2 Department of Hematology, Gustave Roussy Cancer Center, Université Paris-Saclay, Villejuif, France. 3 Division of Hematology/Oncology, The Hospital for Sick Children, Toronto, ON, Canada. 4 The Steve and Cindy Rasmussen Institute for Genomic Medicine, Nationwide Children's Hospital, Columbus, OH, USA.…”
Section: Acknowledgementsmentioning
confidence: 99%
See 1 more Smart Citation
“…2 Department of Hematology, Gustave Roussy Cancer Center, Université Paris-Saclay, Villejuif, France. 3 Division of Hematology/Oncology, The Hospital for Sick Children, Toronto, ON, Canada. 4 The Steve and Cindy Rasmussen Institute for Genomic Medicine, Nationwide Children's Hospital, Columbus, OH, USA.…”
Section: Acknowledgementsmentioning
confidence: 99%
“…Tumours of each organ system and across volumes (blue books) are classified hierarchically within this novel framework along taxonomy principles and a set of nonnegotiables that include process transparency, bibliographic rigor, and avoidance of bias [1,2]. The development of the 5th edition is overseen by an editorial board that includes standing membersrepresentatives from major medical and scientific organizations around the world-who oversee the entire series, in addition to expert members appointed for their leadership and contemporaneous expertise relevant to a particular volume [3]. The editorial board, in turn, identifies authors through an informed bibliometry process, with an emphasis on broad geographic representation and multidisciplinary expertise.…”
Section: Introductionmentioning
confidence: 99%
“…The last edition of the WHO classification of hematolymphoid tumors was the 4 th edition released in 2008 (1), which was revised in 2017 (R4 th WHO-Hem) (2). The electronic version of the 5 th edition of the WHO classification of hematolymphoid tumors (5 th WHO-Hem) was released online in August 2022 (3), and the print version is expected to be out at the end of 2022 (4). The main updates of almost all the entities have been described in two fantastic review articles written by the authors of the 5 th WHO-Hem and published in Leukemia in July of 2022 (5,6).…”
Section: Introductionmentioning
confidence: 99%
“…For MPNs, the WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues—5th edition, 2022, classifies the following hematological malignancies: chronic myeloid leukemia (CML), polycythemia vera (PV), essential thrombocythemia (ET), primary myelofibrosis (PMF), chronic neutrophilic leukemia (CNL), chronic eosinophilic leukemia (CEL), juvenile myelomonocytic leukemia (JMML), and myeloproliferative neoplasm, not otherwise specified (MPN-NOS) [ 6 , 7 ]. The MPN BCR-ABL1 —negative [ 5 ].…”
Section: Introductionmentioning
confidence: 99%